Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in Acquired Hemophilia A
NCT04188639Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of emicizumab in acquired hemophilia A (AHA), sponsored by GWT-TUD. Started Mar 2021; status: completed.
02
Drugs
emicizumab
03
Conditions
acquired hemophilia A (AHA)
Beyond the preview
Go deeper on NCT04188639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188639.